Cullinan Oncology, Inc.
General ticker "CGEM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $514.2M (TTM average)
Cullinan Oncology, Inc. follows the US Stock Market performance with the rate: 4.2%.
Estimated limits based on current volatility of 6.4%: low 9.93$, high 10.97$
Factors to consider:
- Total employees count: 111 (+30.6%) as of 2024
- Top business risk factors: Operational and conduct risks, Third-party risks, Regulatory and compliance, Litigation risks, Supply chain disruptions
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [6.26$, 15.20$]
- 2025-12-31 to 2026-12-31 estimated range: [4.38$, 10.94$]
Financial Metrics affecting the CGEM estimates:
- Negative: with PPE of -3.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.78 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 94.93 > 63.39
- Positive: Industry inventory ratio change (median), % of -0.48 <= -0.15
- Positive: Inventory ratio change, % of 0 <= 0
Short-term CGEM quotes
Long-term CGEM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $-144.65MM | $191.09MM | $196.92MM |
| Operating Income | $144.65MM | $-191.09MM | $-196.92MM |
| Non-Operating Income | $6.67MM | $21.87MM | $29.46MM |
| R&D Expense | $91.95MM | $148.16MM | $142.90MM |
| Income(Loss) | $151.32MM | $-169.22MM | $-167.46MM |
| Taxes | $42.12MM | $-14.12MM | $0.12MM |
| Profit(Loss)* | $111.21MM | $-153.16MM | $-167.38MM |
| Stockholders Equity | $535.03MM | $453.70MM | $590.33MM |
| Assets | $561.12MM | $484.18MM | $621.82MM |
| Operating Cash Flow | $-126.66MM | $-134.28MM | $-145.30MM |
| Capital expenditure | $1.13MM | $0.21MM | $0.00MM |
| Investing Cash Flow | $248.97MM | $35.81MM | $-136.31MM |
| Financing Cash Flow | $-25.93MM | $40.75MM | $266.19MM |
| Earnings Per Share** | $2.46 | $-3.69 | $-3.11 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.